Multidisciplinary Screening for Heart Failure
(MAPLE-CHF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses a computer program to identify potential heart failure patients from medical records, followed by blood tests and AI heart imaging. It targets patients at risk of heart failure to catch the condition early. The process involves scanning records, testing blood for a specific marker, and using AI for detailed heart images if needed.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is the AI-enabled electrocardiogram safe for use in humans?
How is the multidisciplinary screening for heart failure treatment different from other treatments?
This treatment is unique because it combines artificial intelligence with traditional heart tests like echocardiograms and electrocardiograms to improve the detection of heart problems. The AI-enhanced approach can identify heart issues earlier and more accurately, especially in non-cardiology settings, and when combined with natriuretic peptide testing, it offers a more comprehensive screening for heart failure.46789
What data supports the effectiveness of the treatment AI echocardiogram, Artificial Intelligence Echocardiogram, AI Echocardiogram, Electrocardiogram, ECG, 12-lead electrocardiogram, NT-proBNP, N-terminal pro-brain natriuretic peptide, N-terminal prohormone of B-type natriuretic peptide for heart failure?
Research shows that AI-enabled electrocardiograms (ECGs) can accurately predict levels of BNP and NT-proBNP, which are important markers for heart health, and may help monitor cardiovascular disease risk. Additionally, AI ECGs have been effective in detecting heart function issues, like left ventricular systolic dysfunction, which is related to heart failure.14101112
Who Is on the Research Team?
Nathaniel M Hawkins, MD
Principal Investigator
Associate Professor of Medicine, UBC Division of Cardiology
Anique Ducharme, MD
Principal Investigator
Professor of Medicine, Univeriste de Montreal, Montreal Heart Institute
Serge LePage, MD
Principal Investigator
Centre Hospitalier Universite de Sherbrooke-Hopital Fleurimont
Are You a Good Fit for This Trial?
This trial is for adults over 40 with risk factors like coronary artery disease, diabetes, atrial fibrillation, stroke history, regular diuretic use, COPD, peripheral artery disease or chronic kidney disease. It's not for those who can't consent, already have heart failure diagnosis or are on renal replacement therapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Pre-screening
Pre-screening using extracted primary care electronic health records with a case finding algorithm
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants in the intervention arm undergo NT-proBNP testing, and if elevated, receive an AI echocardiogram and ECG
Routine Care
Participants in the routine care arm are monitored for heart failure events
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AI echocardiogram
- Electrocardiogram
- NT-proBNP
AI echocardiogram is already approved in Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cardiology Research UBC
Lead Sponsor
Centre for Cardiovascular Innovation
Collaborator
NHS Greater Glasgow & Clyde
Collaborator
Montreal Heart Institute
Collaborator
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Canadian Heart Function Alliance
Collaborator
HeartLife Foundation
Collaborator